Please provide your email address to receive an email when new articles are posted on . Pegcetacoplan reduced proteinuria in patients with rare complement-mediated glomerular diseases vs. placebo.
The estimated prevalence of aHUS ranges from 0.5 to 2.0 cases per million individuals. 3 Incidences appear comparable across Europe, North America, and Asia, although underdiagnosis is likely, ...
The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...
Light and heavy chain deposition disease (LHCDD) is a clonal plasma cell or monoclonal B-cell dyscrasia characterized by deposition of monoclonal immunoglobulin light and heavy chains. LHCDD mainly ...
The triple therapy showed a 50% overall response rate and 22-month median overall survival in MSS BRAF V600E-mutant mCRC patients. Targeting MAPK signaling with encorafenib and cetuximab may prime ...
ARCHER II trial evaluates vonaprument's efficacy in preventing vision loss in advanced AMD/GA, with over 630 patients enrolled globally. Vonaprument selectively inhibits C1q, addressing ...
ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...
Expert Rev Clin Immunol. 2008;4(3):379-390. Since there are no genetic deficiencies of CRP in man, animal models have been used to study the role of CRP in inflammatory disease. Two methods have been ...
TSP-1 reduced C3 and C5 cleavage and formation of the membrane attack complex, attenuating complement-mediated injury in AAV models. Complement activation is a relevant driver in the pathomechanisms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results